Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1123)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

최신 SEC 제출 서류

CTOR's Discussions on Twitter

CTOR을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR Citius Oncology Inc	1.13	95.82M	0	0	0	0.00
ZTS Zoetis Inc	118.66	51.85B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.33	45.46B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.52	42.70B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	29.79	34.62B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	493.99	21.03B	3.08B	1.24B	1.07B	25.61

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-09-23	업그레이드	Maxim Group	Hold → Buy
2024-11-27	개시	Maxim Group	Buy

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

CTOR을(를) 다른 주식과 비교

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria

Citius Oncology Raises $18M Through Direct Offering - TipRanks

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Benzinga

Citius Oncology (NASDAQ:CTOR) Shares Up 6.4%What's Next? - MarketBeat

Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada

Citius Oncology added to the Russell Microcap Index - MSN

Citius Oncology shares sink after announcing $18M fundraising deal - MSN

Citius Oncology raises $18 million to support cancer therapy launch - Investing.com

Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com South Africa

Citius Oncology stock tumbles after $18M capital raise - Investing.com

Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire

Citius Oncology, Inc. announced that it expects to receive $16.6 million in funding - marketscreener.com

What drives Citius Oncology Inc stock priceStock Price Divergence & Calculate Profit Targets With AI Accuracy - earlytimes.in

Is Citius Oncology Inc a good long term investmentLow Beta Stocks & Free Rapid Profit Acceleration - earlytimes.in

Citius Oncology Launches Lymphir In US For Skin Cancer - MSN

Citius Oncology expands lymphir distribution to Turkey, Middle East By Investing.com - Investing.com Nigeria

Is Citius Oncology Inc. stock a top pick in earnings season2025 Dividend Review & Weekly Top Gainers Alerts - Newser

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus

Citius Oncology expands lymphir distribution to Turkey, Middle East - Investing.com

Citius Oncology expands Lymphir distribution to Turkey and Middle East countries - marketscreener.com

Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries - TradingView

What Wall Street predicts for Citius Oncology Inc. stock priceStop Loss & Growth Focused Stock Pick Reports - Newser

Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ

Citius Oncology enters distribution services agreement with Cardinal Health - MSN

Does Citius Oncology Inc (CTOR) offer a good opportunity for investors? - Setenews

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - marketscreener.com

Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga

Citius launches Lymphir in USA for relapsed or refractory CTCL - The Pharma Letter

Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq

Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN

Will Citius Oncology Inc. stock continue upward momentumJuly 2025 Market Mood & Target Return Focused Picks - Newser

Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Lelezard

CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan

How Citius Oncology Inc. stock performs in weak economyWeekly Earnings Recap & Low Risk High Reward Ideas - Newser

Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma - TipRanks

Citius Oncology, Inc. Announces U.S. Launch of LYMPHIR for CTCL - TradingView

Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com

Citius Oncology announces U.S. commercial launch of Lymphir for cutaneous T-cell lymphoma - marketscreener.com

Citius Oncology stock soars after commercial launch of LYMPHIR therapy By Investing.com - Investing.com South Africa

Citius Oncology stock soars after commercial launch of LYMPHIR therapy - Investing.com

Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment - Seeking Alpha

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a - GuruFocus

Citius Oncology Launches Cancer Drug Lymphir in the US - marketscreener.com

Citius Oncology launches lymphir for cutaneous T-cell lymphoma By Investing.com - Investing.com South Africa

Citius Oncology launches lymphir for cutaneous T-cell lymphoma - Investing.com

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목